CHA2DS2-VASc score predict no-reflow phenomenon in primary percutaneous coronary intervention

被引:26
作者
Mirbolouk, Fardin [1 ]
Gholipour, Mahboobeh [1 ]
Salari, Arsalan [1 ]
Shakiba, Maryam [2 ]
Kheyrkhah, Jalal [1 ]
Nikseresht, Vahid [3 ]
Sotoudeh, Nozar [4 ]
Moghadam, Negar [4 ]
Mirbolouk, Mohammad Jaafar [4 ]
Far, Mani Moayeri [4 ]
机构
[1] Guilan Univ Med Sci, Sch Med, Heshmat Hosp, Cardiovasc Dis Res Ctr,Dept Cardiol, Rasht, Iran
[2] Guilan Univ Med Sci, Cardiovasc Dis Res Ctr, Rasht, Iran
[3] Guilan Univ Med Sci, Hlth Heart Res Ctr, Rasht, Iran
[4] Guilan Univ Med Sci, Dept Cardiol, Cardiovasc Dis Res Ctr, Rasht, Iran
关键词
CHA2DS2-VASc Score; STEMI; Primary PCI; No-reflow;
D O I
10.15171/jcvtr.2018.08
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Introduction: No-reflow is one of the major complications of primary percutaneous coronary intervention (PCI) in patients with acute ST elevation myocardial infarction. This phenomenon is associated with adverse outcomes in these patients. In the current study, we evaluated the effectiveness of CHA2DS2-VASc score in predicting no-reflow phenomenon. CHA2DS2-VASc score is a risk stratification method to estimate the risk of thromboembolism in patients with atrial fibrillation. Methods: In total, 396 patients with ST elevation myocardial infarction who had undergone primary PCI were evaluated in our study. Based on post interventional TIMI flow rate results, the patients were divided into two groups: control group (294 patients) and no-reflow group (102 patients). The CHA2DS2-VASc score was calculated for each participant. Multivariate regression analysis was performed to determine the predictive value of this score. Results: Our findings showed that CHA2DS2-VASc score can predict no-reflow independently (odds ratio [OR]: 3.06, 95% CI: 2.23-4.21, P < 0.001). Moreover, lower systolic blood pressure, higher diastolic blood pressure, grade 0 initial TIMI flow rate and smaller stent size were other independent predictors of the no-reflow in our study. We also defined a cut off value of >= 2 for the CHA2DS2-VASc score in predicting the no-reflow with a sensitivity of 88% and specificity of 67%, area under curve: 0.83 with 95% CI (0.79-0.88). Conclusion: The CHA2DS2-VASc score could be used as a simple applicable tool in the prediction of no-reflow before primary PCI in the acute ST elevation myocardial infarction patients.
引用
收藏
页码:46 / 52
页数:7
相关论文
共 31 条
  • [1] Bleeding complications with the P2Y12 receptor antagonists clopidogrel and ticagrelor in the PLATelet inhibition and patient Outcomes (PLATO) trial (vol 32, pg 2933, 2011)
    Becker, R. C.
    Bassand, J. P.
    Budaj, A.
    Wojdyla, D. M.
    James, S. K.
    Cornel, J. H.
    French, J.
    Held, C.
    Horrow, J.
    Husted, S.
    Lopez-Sendon, J.
    Lassila, R.
    Mahaffey, K. W.
    Storey, R. F.
    Harrington, R. A.
    Wallentin, L.
    [J]. EUROPEAN HEART JOURNAL, 2012, 33 (21) : 2750 - 2750
  • [2] Effect of no-reflow during primary percutaneous coronary intervention for acute myocardial infarction on six-month mortality
    Brosh, David
    Assali, Abid R.
    Mager, Aviv
    Porter, Avital
    Hasdai, David
    Teplitsky, Igal
    Rechavia, Eldad
    Fuchs, Shmuel
    Battler, Alexander
    Kornowski, Ran
    [J]. AMERICAN JOURNAL OF CARDIOLOGY, 2007, 99 (04) : 442 - 445
  • [3] Camm AJ, 2010, EUR HEART J, V31, P2369, DOI [10.1093/eurheartj/ehq278, 10.1093/europace/euq350]
  • [4] A Randomized Trial of Deferred Stenting Versus Immediate Stenting to Prevent No- or Slow-Reflow in Acute ST-Segment Elevation Myocardial Infarction (DEFER-STEMI)
    Carrick, David
    Oldroyd, Keith G.
    McEntegart, Margaret
    Haig, Caroline
    Petrie, Mark C.
    Eteiba, Hany
    Hood, Stuart
    Owens, Colum
    Watkins, Stuart
    Layland, Jamie
    Lindsay, Mitchell
    Peat, Eileen
    Rae, Alan
    Behan, Miles
    Sood, Arvind
    Hillis, W. Stewart
    Mordi, Ify
    Mahrous, Ahmed
    Ahmed, Nadeem
    Wilson, Rebekah
    Lasalle, Laura
    Genereux, Philippe
    Ford, Ian
    Berry, Colin
    [J]. JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2014, 63 (20) : 2088 - 2098
  • [5] The CHADS2 and CHA2DS2-VASc scores predict adverse vascular function, ischemic stroke and cardiovascular death in high-risk patients without atrial fibrillation: Role of incorporating PR prolongation
    Chan, Yap-Hang
    Yiu, Kai-Hang
    Lau, Kui-Kai
    Yiu, Yuen-Fung
    Li, Sheung-Wai
    Lam, Tai-Hing
    Lau, Chu-Pak
    Siu, Chung-Wah
    Tse, Hung-Fat
    [J]. ATHEROSCLEROSIS, 2014, 237 (02) : 504 - 513
  • [6] Independent no-reflow predictors in female patients with ST-elevation acute myocardial infarction treated with primary percutaneous coronary intervention
    Chen, Yundai
    Wang, Changhua
    Yang, Xinchun
    Wang, Lefeng
    Sun, Zhijun
    Liu, Hongbin
    Chen, Lian
    [J]. HEART AND VESSELS, 2012, 27 (03) : 243 - 249
  • [7] Use of CHADS2 and CHA2DS2-VASc Scores to Predict Subsequent Myocardial Infarction, Stroke, and Death in Patients with Acute Coronary Syndrome: Data from Taiwan Acute Coronary Syndrome Full Spectrum Registry
    Chua, Su-Kiat
    Lo, Huey-Ming
    Chiu, Chiung-Zuan
    Shyu, Kou-Gi
    [J]. PLOS ONE, 2014, 9 (10):
  • [8] PREDICTION OF CREATININE CLEARANCE FROM SERUM CREATININE
    COCKCROFT, DW
    GAULT, MH
    [J]. NEPHRON, 1976, 16 (01) : 31 - 41
  • [9] Coronary microvascular dysfunction: an update
    Crea, Filippo
    Camici, Paolo G.
    Merz, Cathleen Noel Bairey
    [J]. EUROPEAN HEART JOURNAL, 2014, 35 (17) : 1101 - +
  • [10] Coronary microvascular dysfunction: sex-specific risk, diagnosis, and therapy
    Dean, Jenna
    Dela Cruz, Sherwin
    Mehta, Puja K.
    Merz, C. Noel Bairey
    [J]. NATURE REVIEWS CARDIOLOGY, 2015, 12 (07) : 406 - 414